



US005650429A

United States Patent [19]

[11] Patent Number: **5,650,429**

Conrad et al.

[45] Date of Patent: **Jul. 22, 1997**

[54] **USE OF DL-(+/-)- α -LIPOIC ACID, D-(+)- α -LIPOIC ACID, α -LIPOIC ACID IN REDUCED OR OXIDIZED FORM OR SALTS FOR TREATING CIRCULATORY DISORDERS**

[75] Inventors: **Frank Conrad**, Frankfurt; **Hermann-August Henrich**, Würzburg; **Wolfgang Geise**, Dippach; **Heinz Ulrich**, Niedernberg, all of Germany

[73] Assignee: **Asta Medica Aktiengesellschaft**, Dresden, Germany

[21] Appl. No.: **554,418**

[22] Filed: **Nov. 8, 1995**

[30] **Foreign Application Priority Data**

Nov. 8, 1994 [DE] Germany 44 39 477.2

[51] **Int. Cl.**⁶ **A61K 31/385**

[52] **U.S. Cl.** **514/440**

[58] **Field of Search** 514/440

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,318,987 6/1994 Weithmann et al. 514/457

OTHER PUBLICATIONS

The Merck Index, 11th edition, p. 1469, cit#9255 1989.

WPI Abstract of Canadian Patent 2133861 (Koel Tringer) Apr. 1995.

Primary Examiner—Raymond Henley, III
Attorney, Agent, or Firm—Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

[57] **ABSTRACT**

The invention relates to the use of DL-(+/-)- α lipoic acid, D-(+)- α -lipoic acid, L-(+)- α -lipoic acid in reduced or oxidized form or of the metabolites and salts, esters, amides thereof for the preparation of medicines for the treatment of disorders caused by changes or disturbances in the rheological properties of the blood such as blood viscosity, erythrocyte flexibility and the aggregation of erythrocytes, in particular for the treatment of microangiopathy with disturbed microcirculation. It can also be used in the treatment of diabetics and of dialysis patients for protection of the erythrocytes, in central and peripheral circulatory disturbances and in tinnitus and hearing loss.

8 Claims, No Drawings